)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Decoy Therapeutics
Decoy Therapeutics (DCOY) investor relations material
Decoy Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Preclinical-stage pipeline centers on the IMP³ACT peptide-conjugate platform and Designable Multi-Antivirals for respiratory viruses; no products are approved and no product-sales revenue has been generated.
Portfolio also includes SP-3164 and SP-2577; efforts are focused on integrating SP-3164 into peptide-based PROTACs, while seeking strategic alternatives for SP-2577.
Financial highlights
Q3 2026 grant revenue was $307,430, all from the Gates Foundation, versus $0 in Q3 2025; net loss was $2.99 million versus $873,467.
Q3 R&D expense rose to $1.57 million from $61,826 and G&A expense to $1.75 million from $833,304, largely reflecting the post-merger addition of Legacy Decoy operations and the IMP³ACT program.
9M 2026 grant revenue was $535,059 versus $0; net loss was $7.59 million versus $3.54 million, with R&D of $3.63 million and G&A of $4.61 million.
9M operating cash use was $8.13 million versus $3.69 million; cash, cash equivalents and restricted cash fell to $8.17 million from $10.71 million at year-end 2025.
Outlook and guidance
Higher R&D expense is expected in upcoming quarters as development advances toward an IND filing with the FDA, or equivalent CTA, in H2 2027.
Current cash resources are expected to fund current and restructured operations into early 2027; additional capital is needed to fund continued development and operations.
Grant revenue may fluctuate with development stage and timing of qualifying expenses; no product-sales revenue is expected until a candidate receives regulatory approval and is commercialized.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Decoy Therapeutics
- A large warrant-share resale registration meets acute liquidity and Nasdaq-listing risks.DCOY
Registration filing - Q2 2026 net loss widened to $2.4M; cash runway extends into late 2026, but funding risks persist.DCOYQ2 2026
- Shareholders to vote on warrant exercises and share reduction, impacting future funding.DCOYProxy filing
- Shareholders will vote on warrant exercises, share reduction, and adjournment at a virtual meeting.DCOYProxy filing
- Shareholders will vote on warrant exercises, reducing authorized shares, and meeting adjournment.DCOYProxy filing
- AI-driven biotech with liquidity risks and large warrant overhang, reliant on future warrant proceeds.DCOYRegistration filing
- Equity line offering raises up to $5M, with major dilution and liquidity risks for shareholders.DCOYRegistration filing
- Shareholders to vote virtually on directors, executive pay, and auditor ratification for 2026.DCOYProxy filing
- Annual meeting to vote on directors, executive pay, and auditor, with strong governance and oversight.DCOYProxy filing
Decoy Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Salarius Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers with unmet medical needs. The company specializes in epigenetic-based treatments, aiming to inhibit key cancer-related pathways and improve patient outcomes. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.